Ophthalmic surgery is generally performed in elderly people, many of whom are on systemic medications such as antiplatelet and anticoagulant therapies. These drugs are routinely discontinued preoperatively to prevent severe intra-and post-operative bleeding. Nonetheless, premature discontinuation of antiplatelet therapy or interruption of anticoagulation increases the risk of thromboembolic complications including death. It is important to balance the risk of thrombotic complications and the benefit of avoiding intra-and post-operative bleeding.
Antiplatelet drugs such as aspirin and clopidogrel are prescribed for patients with atherosclerotic vascular disease and/or for prevention of acute coronary syndrome, myocardial infarction, or stroke. Patients with coronary artery disease are often prescribed dual antiplatelet therapy that combines aspirin and clopidogrel for a mandated duration after an acute coronary syndrome or stent (drug-eluting or bare-metal) implantation. Premature discontinuation of antiplatelet therapy may lead to major cardiac complications and thrombotic events (myocardial infarction, stent thrombosis, and non-fatal stroke) and even death. 1 Anticoagulant treatments such as vitamin K antagonist (e.g. warfarin) and the novel oral anticoagulants (NOACs) [e.g. dabigatran, rivaroxaban, apixaban, and edoxaban] have been widely used in patients with atrial fibrillation to prevent stroke or systemic embolism, in patients with valvular heart disease after mechanical prosthetic heart valve replacement, and for venous thromboembolism prophylaxis. Patients on anticoagulants are risk-stratified for better perioperative anticoagulant management. The risk of thromboembolic events in patients with a history of atrial fibrillation can be assessed using the CHADS2 score. The thrombotic risk is highest in those with mitral valve prosthesis, older aortic valve prosthesis, and recent stroke or transient ischemic attacks or venous thromboembolic events. As interruption of anticoagulation therapy increases the risk of potentially fatal thromboembolic events, the medical team needs to consider the thrombotic risk based on patient-related and surgeryrelated factors before continuing or stopping anticoagulation. Oral anticoagulants are generally continued perioperatively for minor procedures, whereas invasive procedures may require discontinuation of oral anticoagulants or bridging anticoagulation therapy with subcutaneous low-molecularweight heparin or intravenous unfractionated heparin during interruption of anticoagulation.
Cataract surgery is commonly performed in elderly patients on antithrombotic therapy. The management of antiplatelet and anticoagulation therapies perioperatively in cataract surgery has been well-studied.
2-4 Cataract removal is an avascular procedure with topical anesthesia, with or without intracameral anesthesia. No significantly increased risk of severe bleeding or sight-threatening bleeding complications is associated with antithrombotic treatment, although there may be an increase in the incidence of non-significant or selflimiting hemorrhage such as hyphema or subconjunctival hemorrhage. A Hong Kong study reported no difference in hemorrhagic complications between cases continuing or withholding NOAC during phacoemulsification.
5
Vitreoretinal (VR) surgery also appears to be safe in patients on antithrombotic therapy. Nonetheless, the literature lacks evidence with strong statistical power to formulate guidelines on perioperative management of antithrombotic therapy for VR surgeries. Anticoagulant drugs are associated with an increased risk of intraocular hemorrhage, but not with serious consequences, re-operations, or surgery failure. [6] [7] [8] In a systematic review and meta-analysis, NOACs were reported to reduce the risk of intraocular bleeding by approximately 20% when compared with warfarin. 9 Further studies of the effects of NOACs on the outcome of VR surgery are needed. In patients on warfarin, VR surgery has been shown to result in no anesthesia-related or intraoperative hemorrhagic complications despite some postoperative hemorrhages that resolved spontaneously. Similarly, in systemically anticoagulated patients receiving intravitreal injections, the risk of hemorrhagic complications is extremely low; cessation of anticoagulation therapy is not needed. [10] [11] [12] The benefits of continuing antithrombotic therapy outweigh the risks of discontinuation.
Trabeculectomy or a glaucoma drainage device may result in large variation in intraocular pressure during and after glaucoma surgery. Anticoagulation can thus increase the risk of certain vision-threatening complications such as suprachoroidal hemorrhage. Bleeding can negatively impact the surgical outcome and lead to surgical failure. Intraoperative bleeding, particularly in the subconjunctival space, may impede surgeon visualization of tissues. The proinflammatory nature of bleeding can result in excessive scarring. Blood clots can mechanically block the drainage site at the sclerostomy or tube opening. Patients on anticoagulation therapy have been reported to have an increased postoperative hyphema rate, with or without a significant impact on the final surgical outcome. 13, 14 As the evidence for altering anticoagulation therapy for glaucoma surgery is lacking, different surgeons adopt different practices. Consultation with the primary prescriber of anticoagulation therapy is recommended before alteration.
There is a lack of evidence on which to base guidelines for perioperative management of oculoplastic patients on antithrombotic therapy. The incidence of serious hemorrhagic Patients on antithrombotic agents or not are comparable in terms of perioperative hemorrhagic complications. 16 In patients undergoing oculoplastic procedures with a greater hemorrhagic risk such as dacryocystorhinostomy or orbital decompression, surgeons generally suggest stopping antithrombotic agents if it is safe to do so. 17 Alteration of the antithrombotic therapy should be discussed with the patient and individualized based on the nature of surgery and the patient's medical condition and need for anticoagulation.
For most types of ophthalmic procedures, the risks of interrupting antithrombotic therapy appear to outweigh the benefits. Aspirin does not appear to be associated with an increased risk of significant bleeding in patients undergoing any type of ophthalmic surgery. Similarly, warfarin does not appear to increase the risk of bleeding in ophthalmic surgery when the international normalized ratio is within the normal range. In glaucoma or oculoplastic surgeries where bleeding at the operative site may impact the surgical outcome, perioperative alteration of anticoagulation therapy may be performed cautiously and should involve the opinion of a medical specialist. Nonetheless, the evidence on which to base precise recommendations about NOACs is lacking. Further investigations are needed to explore the risk of significant bleeding when altering NOAC therapy.
A collaboration between the Hong Kong Eye Hospital and the Department of Medicine, Queen Elizabeth Hospital aims to design a guideline to standardize and simplify the perioperative antithrombotic management in ophthalmic surgeries. The suggested algorithms for perioperative management of antiplatelet, warfarin, and NOAC therapies are shown in Tables 1 to 4.
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